XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2018
Jun. 30, 2017
Current assets:    
Cash and cash equivalents $ 97.4 $ 102.4
Marketable investment securities 59.9 48.3
Prepaid expenses 10.1 12.7
Inventory 33.4 42.2
Trade accounts receivable, less allowance for doubtful accounts of $10.3 March 31, 2018 and $8.2 June 30, 2017 123.7 105.6
Prepaid taxes 3.7 0.2
Other receivables 3.3 5.7
Total current assets 331.5 317.1
Property, plant and equipment, net 48.2 51.1
Long-term marketable investment securities 51.3 48.5
Intangibles, net 467.3 491.6
Goodwill 320.2 316.1
Total assets 1,218.5 1,224.4
Current liabilities:    
Accounts payable 20.2 22.0
Accrued liabilities 64.1 65.6
Short-term contingent consideration 7.4 127.3
Deferred revenue 2.6 2.6
Total current liabilities 94.3 217.5
Unrecognized tax benefits 27.9 25.2
Other long-term liabilities 6.8 7.2
Contingent consideration 9.6 13.2
Long-term debt 69.3 99.1
Long-term deferred taxes 62.2 84.4
Total liabilities 270.1 446.6
Commitments and contingencies
Stockholders’ equity:    
Common stock, 69.9 and 68.4 shares outstanding at March 31, 2018 and June 30, 2017 respectively 0.7 0.7
Additional paid-in capital 889.6 851.4
Accumulated other comprehensive income (loss) 1.8 (5.5)
Retained earnings (deficit) 56.2 (68.4)
Total Myriad Genetics, Inc. stockholders’ equity 948.3 778.2
Non-Controlling Interest 0.1 (0.4)
Total stockholders' equity 948.4 777.8
Total liabilities and stockholders’ equity $ 1,218.5 $ 1,224.4